1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow PHA-568487E: new trials by email Literature Review of PHA-568487E trials Research Report on PHA-568487E
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia NLX-112, Placebo - Medication-Induced Dyskinesia | Phase 2 | Completed | Neurolixis SAS | 27 | 2021-11-09 | 2024-04-23 |
Dyskinesia, Drug-Induced (1) · Dyskinesias (1) · Parkinson Disease (1)
Neurolixis SAS (1)
Sweden (1)
Adrian Newman-Tancredi, PhD (1) · Per Svenningsson, Professor (1)